Patents Assigned to Bolt Biotherapeutics, Inc.
-
Publication number: 20220226492Abstract: The invention provides an immunoconjugate of formula (I) or (II). Antibody-adjuvant immunoconjugates of the invention, comprising an antibody construct that has an antigen binding domain that binds human epidermal growth factor receptor 2 (“HER2”) linked to one or more adjuvants, demonstrate superior pharmacological properties over conventional antibody conjugates. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.Type: ApplicationFiled: March 13, 2020Publication date: July 21, 2022Applicants: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior UniversityInventors: Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Romas Kudirka, Arthur Lee, Brian Safina, Matthew Zhou, Edgar George Engleman
-
Publication number: 20220226491Abstract: The invention provides an immunoconjugate of formula (I) or (II). Antibody-adjuvant immunoconjugates of the invention, comprising an antibody construct that has an antigen binding domain that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants, demonstrate superior pharmacological properties over conventional antibody conjugates. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.Type: ApplicationFiled: March 13, 2020Publication date: July 21, 2022Applicants: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior UniversityInventors: Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Justin Kenkel, Romas Kudirka, Arthur Lee, Brian Safina, Matthew Zhou, Edgar George Engleman
-
Publication number: 20220195066Abstract: The invention provides immunoconjugates of Formula I comprising an anti-CEA antibody linked by conjugation to one or more 8-Het-2-aminobenzazepine derivatives. The invention also provides 8-Het-2-aminobenzazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.Type: ApplicationFiled: December 9, 2021Publication date: June 23, 2022Applicant: BOLT BIOTHERAPEUTICS, INC.Inventors: Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Marcin Kowanetz, Romas Kudirka, Arthur Lee, William Mallet, Brian Safina, Matthew Zhou
-
Publication number: 20220152215Abstract: The invention provides an immunoconjugate of formula (I) or (II) Antibody-adjuvant immunoconjugates of the invention, comprising an antibody construct that has an antigen binding domain that binds carcinoembryonic antigen (“CEA”) linked to one or more adjuvants, demonstrate superior pharmacological properties over conventional antibody conjugates. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.Type: ApplicationFiled: March 13, 2020Publication date: May 19, 2022Applicants: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior UniversityInventors: Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Marcin Kowanetz, Romas Kudirka, Arthur Lee, William Mallet, Brian Safina, Matthew Zhou, Edgar George Engleman
-
Publication number: 20220153849Abstract: The invention relates to dendritic cell-associated C-type lectin 2 (Dectin-2) binding agents, nucleic acids comprising the inventive binding agents, vectors and cells comprising the inventive nucleic acids, and compositions thereof. The invention also relates to methods of providing the inventive binding agents, methods for treating a disease, disorder, or condition in a mammal, and methods of stimulating an antigen presenting cell.Type: ApplicationFiled: February 3, 2022Publication date: May 19, 2022Applicant: Bolt Biotherapeutics, Inc.Inventors: Shelley Erin Ackerman, David Dornan, Karla A. Henning, Justin A. Kenkel
-
Publication number: 20220143012Abstract: The invention provides a macromolecule-supported compound of formula (I) or (II). Macromolecule-supported compounds of the invention, comprising macromolecular support linked to one or more TLR agonists, are recognized by TLRs (e.g., TLR7 and/or TLR8) with high affinity providing utility in therapeutics, diagnostics, and chemical assays. The invention further provides compositions comprising and methods of treating cancer with the macromolecule-supported compounds.Type: ApplicationFiled: March 13, 2020Publication date: May 12, 2022Applicants: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior UniversityInventors: Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Justin Kenkel, Romas Kudirka, Arthur Lee, Brian Safina, Matthew Zhou, Edgar George Engleman
-
Publication number: 20220001022Abstract: The invention provides an immunoconjugate of formula: or pharmaceutically acceptable salt thereof, wherein subscript r is an integer from 1 to 10, subscript n is an integer from about 2 to about 25, and “Ab” is an antibody construct that has an antigen binding domain that binds HER2. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.Type: ApplicationFiled: September 2, 2021Publication date: January 6, 2022Applicants: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior UniversityInventors: Shelley Erin Ackerman, Michael N. Alonso, David Y. Jackson, Arthur Lee, Edgar George Engleman
-
Publication number: 20210284750Abstract: A method for producing an immunoconjugate, the method comprising combining one or more compounds of Formula I and an antibody of Formula II, wherein Formula II is an antibody with one or more lysine residues, in an aqueous solution buffered at a pH of about 7.5 to about 9 until at least 33 mol % of the one or more compounds of Formula I is conjugated to the antibody of Formula II to provide the immunoconjugate of Formula III, wherein Adj is an adjuvant, Z is —CH2—, —C(O)NH—, —C(O)O—, or —C(O)—, L is a linker, E is an ester, and r is the average number of adjuvants attached to the antibody and is a positive number up to about 8, in a first buffered aqueous solution.Type: ApplicationFiled: April 16, 2018Publication date: September 16, 2021Applicant: Bolt Biotherapeutics, Inc.Inventors: David Y. Jackson, Michael N. Alonso, Arthur Lee, Richard P. Laura
-
Patent number: 11110178Abstract: The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via the linker. Methods for treating cancer with the immunoconjugates of the invention are also described.Type: GrantFiled: March 13, 2020Date of Patent: September 7, 2021Assignees: The Board of Trustees of the Leland Standford Junior University, BOLT BIOTHERAPEUTICS, INC.Inventors: Michael Nathaniel Alonso, Edgar George Engleman, Shelley Erin Ackerman, Justin Kenkel, Arthur Lee, David Y. Jackson
-
Publication number: 20210187115Abstract: The invention provides an immunoconjugate of formula: (I), or pharmaceutically acceptable salt thereof, wherein subscript r is an integer from 1 to 10, subscript n is an integer from about 2 to about 50, “Adj” is an adjuvant moiety, and “Ab” is an antibody construct that has an antigen binding domain that binds EGFR. The invention also provides compositions comprising the immunoconjugate. The invention further provides methods of treating cancer with the immunoconjugate.Type: ApplicationFiled: August 29, 2019Publication date: June 24, 2021Applicants: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior UniversityInventors: Michael N. Alonso, Edgar George Engleman, David Y. Jackson, Arthur Lee, Shelley Erin Ackerman
-
Publication number: 20210154316Abstract: The invention provides an immunoconjugate comprising (a) an antibody construct comprising (i) an antigen binding domain and (ii) an Fc domain and (b) 1-8 adjuvant cores, wherein each adjuvant core is covalently bonded to the antibody construct via a linker, wherein each adjuvant core comprises a 2-amino nitrogen moiety with a pendant nitrogen atom and a point of attachment of the linker to the adjuvant core, and wherein the distance between the pendant nitrogen atom and the point of attachment of the linker is greater than about 5 ?. The invention also provides methods for treating cancer with the immunoconjugates.Type: ApplicationFiled: May 17, 2019Publication date: May 27, 2021Applicants: Bolt Biotherapeutics, Inc., The Board of Trustees of the Leland Stanford Junior UniversityInventors: Michael N. Alonso, David Y. Jackson, Brian Safina, Shelley Erin Ackerman, Edgar George Engleman
-
Publication number: 20210128744Abstract: The invention provides immunoconjugates of Formula I comprising an antibody linked by conjugation to one or more thienoazepine derivatives. The invention also provides thienoazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.Type: ApplicationFiled: October 23, 2020Publication date: May 6, 2021Applicant: BOLT BIOTHERAPEUTICS, INC.Inventors: Romas Kudirka, Brian Safina
-
Publication number: 20200390899Abstract: The invention provides immunoconjugates of Formula I or III comprising an antibody linked by conjugation to one or more aminobenzazepine derivatives. The invention also provides aminobenzazepine derivative intermediate compositions of Formula II comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.Type: ApplicationFiled: June 12, 2020Publication date: December 17, 2020Applicant: BOLT BIOTHERAPEUTICS, INC.Inventors: Shelley Erin Ackerman, Michael N. Alonso, Romas Kudirka, Arthur Lee, Brian Safina, Matthew Zhou
-
Patent number: 10675358Abstract: The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via the linker. Methods for treating cancer with the immunoconjugates of the invention are also described.Type: GrantFiled: September 24, 2018Date of Patent: June 9, 2020Assignees: The Board of Trustees of the Leland Stanford Junior University, Bolt Biotherapeutics, Inc.Inventors: Michael Nathaniel Alonso, Edgar George Engleman, Shelley Erin Ackerman, Justin Kenkel, Arthur Lee, David Y. Jackson
-
Publication number: 20200108151Abstract: The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via the linker which comprises an ethylene glycol group or glycine residue. Methods for treating cancer with the immunoconjugates of the invention are also described.Type: ApplicationFiled: December 20, 2019Publication date: April 9, 2020Applicant: Bolt Biotherapeutics, Inc.Inventors: David Y. Jackson, Michael Nathaniel Alonso, Arthur Lee
-
Publication number: 20190015516Abstract: The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via the linker which comprises an ethylene glycol group or glycine residue. Methods for treating cancer with the immunoconjugates of the invention are also described.Type: ApplicationFiled: September 12, 2018Publication date: January 17, 2019Applicant: Bolt Biotherapeutics, Inc.Inventors: David Y. Jackson, Michael Nathaniel Alonso, Arthur Lee